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Abstract. Non-small cell lung cancer (NSCLC) is the
commonest cause of cancer mortality worldwide. Growth
factor receptor signalling pathways constitute an important
mediator for tumor growth and proliferation. PTEN and
pAKT play important roles in regulating signal transduction
along this pathway. Separate cohorts of stage I (n=25) and
stage IV (n=34) NSCLC were examined by immunohisto-
chemistry for PTEN and pAKT expression. There was no
correlation between PTEN expression and pAKT expression
and neither were associated with age, sex or smoking status.
Patients with stage IV disease who overexpressed pAKT (at
least 2+) or were PTEN-null had poorer overall survival and
progression-free survival. This suggests that PTEN-null or
pAKT-positive tumors constitute more aggressive tumors
whose clinical course is not altered by therapy. There was
no difference in the clinical outcome for stage I disease by
PTEN or pAKT expression. A greater proportion of the stage
IV patients had PTEN-null disease compared to the stage I
cohort, suggesting that loss of PTEN is important in the tumor
biology of advanced disease. Loss of PTEN or overexpression
of pAKT predicts for an aggressive subset of lung tumors that
have a poor prognosis. This will allow identification of a poor
prognosis subset that can be targeted with novel treatments
that either restore PTEN function or target activated AKT,
mTOR and other downstream signal transduction molecules.
Introduction
Cancer is driven by many mechanisms of growth (1). Of these,
the epidermal growth factor receptor (EGFR) driven pathway
in non-small cell lung cancer is recognized as important for
tumor proliferation. Targeting this pathway has become a
subject of intense interest and frustration for clinical investi-
gators. Unlike in breast cancer where careful selection of
patients for overexpression of Her2 by fluorescent in situ
hybridization (FISH), predicts for benefit both in the metastatic
and adjuvant setting (2-4), overexpression of EGFR does not
successfully predict for treatment advantage with targeted
therapeutics in NSCLC (5). With non-small cell lung cancer
(NSCLC), the search for a similar marker along the EGFR
pathway of sufficient impact is ongoing. The advent of EGFR
tyrosine kinase inhibitors (TK-I) and the hope generated in
the responses seen was increased further by the description of
somatic mutations in the epidermal growth factor receptor
(EGFR) tyrosine kinase binding domain (5,6) that associated
strongly with response. However, there are several caveats
that potentially limit its usefulness as a pharmacogenetic test.
These include low population prevalence in certain ethnicities
(Caucasians, African Americans) (7), unpredictable genotype-
response relationships, difficulties in access to tissue and
facilities for mutation profiling, and resected NSCLC with
specific mutations (e.g., L858R, Exon 19 deletion) appear
to have a better or worse survival independent of any TK-
inhibitor treatment (7) compared to wild-type EGFR suggesting
that these mutations affect prognosis as well as predict for
treatment efficacy.
It is therefore of interest to develop in patients with NSCLC
other markers that predict for prognosis and also treatment
efficacy with EGFR TK-inhibitors. One way is to identify
phosphorylated downstream signal molecules along the EGFR
pathway that indicate potentially active pathways that may
be inhibited by small molecule TK-inhibitors. AKT (protein
kinase B) is a serine-threonine kinase that is activated by
phosphatidylinositol-3 kinase and sits along the EGFR signal
cascade. In turn it phosphorylates a host of other kinases
including the mammalian target of rapamycin (mTOR). One
convenient way to identify the presence of activated AKT is
by immunohistochemistry for the phosphorylated protein.
Some investigators have associated phosphorylation of AKT
on immunohistochemistry with gefitinib efficacy. There was
significant association of pAKT expression with non-smoking
status, adenocarcinoma and female sex (8,9). Of significance,
one of the pathways by which AKT is negatively regulated is
through PTEN.
PTEN is a tumor suppressor gene located on chromosome
10. However loss of function mutations are of very low
frequency in NSCLC in comparison to its loss of expression,
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suggesting that other genetic and epigenetic phenomenon, e.g.
methylation, play a role in inactivating PTEN as well. Loss of
PTEN expression is frequent in prostate (10) and cervical
cancer (11). PTEN down-regulates the AKT and PI3K
(phosphatidylinositol-3 kinase) pathways (12,13). PTEN-null
tumors have therefore greater proliferative activity, growth
and survival. Putatively PTEN inactivation results in active
AKT and other downstream molecules that could therefore
be used as biomarkers of TK-inhibitor response.
We conducted an exploratory analysis of a cohort of
resected stage I non-small cell lung cancer patients and late-
stage (stage IV) patients, to determine if differential expression
of pAKT and its negative regulator PTEN in tumors had any
impact on prognosis in a cohort of early- and late-stage patients
with NSCLC.
Materials and methods
Patients and tissue. Two cohorts of patients were selected.
An early-stage cohort with stage I NSCLC resected at Barnes-
Jewish Hospital and a late-stage cohort consisting of patients
with stage IV NSCLC treated with gefitinib in Siteman Cancer
Center were identified. Clinical data was retrieved from case
records available at the Barnes-Jewish Hospital and the Siteman
Cancer Center. In the stage I cohort, the clinical end-points
used were time to relapse of disease and overall survival.
Patients were included only if they had complete follow-up
information. For the stage IV cohort, clinical end-points
included response as defined by RECIST (14) and duration
of both overall survival and progression-free survival. There
were 69 patients with stage I disease resected between 1998
and 2000 where 5-year follow-up data was available, and 270
patients with stage IV disease treated with gefitinib between
2000 and 2004. Only 130 patients had available formalin-
fixed and paraffin-embedded tissue in the Surgical Pathology
Tissue Bank for the study. Paraffin embedded tissue on slides
was reviewed by two independent surgical pathologists (CRM,
WHZ) unaware of the clinical outcome.
Of these 130 tissue samples, only 49 patients with stage
IV disease and 34 patients with stage I disease had tissue
sufficient for IHC scoring. Patients were further excluded
from clinical outcome analysis if there was incomplete follow-
up information. This resulted in attrition of patient numbers
to 25 patients in the late-stage cohort and 34 patients in the
early-stage cohort. The patient characteristics of each cohort
are shown in Table I.
Immunohistochemistry. Polyclonal rabbit anti-PTEN anti-
body (PAD:PN37) was purchased from ZYMED laboratories
(San Francisco, CA). Phospho-AKT (Ser473) antibodies were
from Cell Signaling (Beverly, MA). Reagents for immuno-
histochemistry were purchased from BioGenex. Immuno-
histochemistry was performed using the streptavidin biotin
complex method on a BioGenex i6000™ automated staining
system based on protocols provided by the manufacturer
(BioGenex, San Ramon, CA). The primary antibodies were
diluted 1:50. The secondary antibody was purchased from
BioGenex and ready to use without dilution. Slides were
scanned with Nikon Eclips (E800) using a MetaMorph Imaging
System.
A semi-quantitative assessment of protein expression was
used to score PTEN and pAKT in lung tissue (15). The
intensity of staining was scored as 0 (negative), 1 (weak), 2
(medium) and 3 (strong). The extent of staining was scored
as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-
100%), according to the percentage of cells stained positive
for each protein. The sum of the intensity and extent scores
was used as the final score (0-7). Tissues having a final score
>2 were considered positive. Final scores of 2-3 were
considered +, 4-5, ++; and 6-7, +++. Phosphorylated AKT
was considered overexpressed if the final score was at least
++, and PTEN was considered expressed if at least +.
Statistical analysis. Results were analyzed using SPSS version
12 (Chicago, IL). ¯2 tests and Fisher's exact test were used to
determine significant differences between populations. Survival
analyses were determined using Kaplan-Meier methods.
Results
Expression of PTEN and pAKT. There were no significant
differences in expression of pAKT or PTEN in relation to
smoking status, gender or histological subtypes (Table II).
However PTEN was present in a greater percentage of patients
in the stage I cohort compared with the stage IV cohort (85%
vs. 68%; p=0.12). pAKT was also overexpressed in only 8%
of the stage IV cohort as compared to 26% of the early-stage
cohort (p=0.18). No relationship between pAKT and PTEN
expression was observed.
PTEN/pAKT and clinical end-points. The two cohorts were
analyzed for any association between clinical outcomes and
PTEN and pAKT expression. In the late-stage cohort, the
single patient with a partial response was a non-smoking
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Table I. Patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––
Stage I cohort Stage IV cohort
(n=34) (n=25)
–––––––––––––––––––––––––––––––––––––––––––––––––








Current or former 15 22
smoker
Never smoker 15 3
Unknown 4 0
–––––––––––––––––––––––––––––––––––––––––––––––––
AC, adenocarcinoma; SCC, squamous cell carcinoma; LC, large
cell; NOS, neuroendocrine.
–––––––––––––––––––––––––––––––––––––––––––––––––
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female with bronchioloalveolar carcinoma. She had 1+ pAKT
and 1+ PTEN staining. Six patients had stable disease, of
whom only one had 2+ staining for pAKT and all others had
weak or no staining, however 5/6 of them stained for PTEN.
A number of tumors that had no pAKT staining achieved
stable disease (Table III). Patients who overexpressed pAKT
of at least 2+ or had PTEN-null tumors on IHC demonstrated
significantly worse disease-free and overall survival from the
point of diagnosis of cancer (Fig. 1). In the stage IV cohort,
the median survival of the PTEN-null group was 1.2 years as
compared with 3.0 years for the PTEN-positive group. The
median survival for the group with pAKT overexpression was
0.5 months as opposed to 3 years where the pAKT expression
was <2+. In the early-stage cohort, there was no significant
difference in overall survival in relation to the expression of
PTEN or pAKT expression, however there was a trend to
better overall survival in the PTEN-positive group (6.0 vs.
1.7 years; p=0.40). Lack of PTEN expression did not impact
the time to relapse (p=0.74).
Discussion
This study was aimed at exploring the differential impact of
PTEN or pAKT on prognosis in early- and late-stage non-
small cell lung cancer. Stage IV tumors that overexpressed
pAKT or were PTEN-null had poorer overall survival. PTEN-
null tumors also had a shorter progression-free survival com-
pared to PTEN expressing tumors. This suggests that PTEN-
null tumors constitute a more aggressive tumor, whose course
is not altered by gefitinib therapy. This resistant phenotype
may yet be overcome by restoring PTEN function. Indeed
PTEN-null cells have demonstrated resistance to EGFR TK-
inhibitors (16) and conversely sensitivity to gefitinib has
been restored in PTEN-null cells by reconstitution of PTEN
(17,18). In the current study, a smaller percentage of tumors
were PTEN-null compared to stage IV tumors. This suggests
that loss of PTEN is likely a late event in the development of
NSCLC. Patients with early-stage disease and loss of PTEN
did not have a shorter time to relapse. Loss of PTEN similarly
carried no prognostic significance in early-stage disease in
previous studies (19). Contrast this to Bepler et al, in whose
study using univariate analysis high RRM1 and PTEN RNA
expression by real-time polymerase chain reaction predicted
for better overall and disease-free survival in patients with
resectable (majority stage IA/B) NSCLC (20). Apart from the
different method used to quantify PTEN expression, in the
multivariate analysis, only high expression of RRM1 predicted
for good prognosis. The poor prognostic value of pAKT
overexpression and PTEN loss is further suggested by a
recent study of NSCLC (21) which demonstrated similar
findings to ours of an increasing loss of PTEN as stage
advances. However, that study also demonstrated a clear
inverse relationship between pAKT and PTEN expression
which was not demonstrated in the current study, probably
because the sample size was small and also because in sporadic
cancers there are other upstream perturbations by which
phosphorylation of AKT can occur other than via repression
of the PTEN-PI3K pathway (22-24). Together with these
studies, our results suggest that PTEN and its function is
more commonly lost in advanced disease and predicts for an
aggressive phenotype in the late stages of NSCLC.
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Table II. Immunohistochemistry and patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Stage I cohort (n=34) Stage IV cohort (n=25)
–––––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––––––––––––––––––
pAKT PTEN pAKT PTEN
–––––––––––––––––– ––––––––––––––––––– ––––––––––––––––––– –––––––––––––––––––
- + ++ +++ - + ++ +++ - + ++ +++ - + ++ +++
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Histology
Adenocarcinoma 3 5 1 1 3 5 2 0 2 11 1 0 10 15 4 1
BAC 0 2 0 1 0 1 1 1 0 1 0 0 1 1 0 0
Large cell/ 0 0 1 0 0 1 0 0 0 4 0 0 2 3 1 0
neuroendocrine
Squamous 3 12 2 3 2 12 4 2 1 4 1 0 2 5 2 1
Male 3 7 1 2 2 7 3 1 1 11 0 0 4 6 2 0
Female 3 12 3 3 3 12 4 2 2 9 2 0 4 7 2 0
Smoker 4 8 4 2 3 6 4 2 3 17 2 0 7 11 4 0
Never smoker 5 13 2 2 2 11 0 2 0 3 0 0 1 2 0 0
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table III. Immunohistochemistry and best response to gefitinib




- + ++ +++ - + ++ +++
–––––––––––––––––––––––––––––––––––––––––––––––––
PR 0 1 0 0 0 1 0 0
PD 0 17 1 0 7 8 3 0
SD 3 2 1 0 1 4 1 0
–––––––––––––––––––––––––––––––––––––––––––––––––
PR, partial response; SD, stable disease.
–––––––––––––––––––––––––––––––––––––––––––––––––
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A number of patients in the stage IV cohort of patients
achieved disease stabilization in the absence of pAKT over-
expression on IHC. This suggests that gefitinib may yet
function in ways independent of an activated pAKT pathway
and patients cannot be selected for therapy based on pAKT
by IHC alone. Indeed, pAKT-positive tumors, in the absence
of somatic mutations in the EGFR TK binding domain, do not
fare well when treated with gefitinib (25). Taken together,
pAKT alone is not a sufficiently good predictive marker of
gefitinib response.
We acknowledge that the sample size in this study was
small and its retrospective nature did not take into account
clinical prognostic factors such as performance status and
weight loss. However, the present results add to the growing
evidence that PTEN and pAKT are important determinants
of prognosis in patients with advanced non-small cell lung
cancer. Loss of PTEN or overexpression of pAKT predicts
for an aggressive subset of lung tumors that have a poor
prognosis. Identifying this subset using IHC is easy to do,
and reproducible. This will allow identification of a poor
prognosis subset that can be targeted with novel treatments
that either restore PTEN function or target activated AKT,
mTOR and other downstream signal transduction molecules.
So far the lung cancer patient populations where PTEN and
pAKT have been studied are small (<100). Larger patient
populations with advanced lung cancer stratified for uniform
stage and therapy need to be examined for these biomarkers
to validate their importance as a prognostic factor in NSCLC.
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